List view / Grid view
A growing body of evidence pinpoints neuroinflammation as a pivotal factor driving brain-related pathogenesis. Yet, a crucial question lingers: among the various immune cell groups residing within the brain, which one orchestrates this inflammatory reaction?
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
The field of cell therapy has emerged as a beacon of hope, promising transformative treatments for various diseases. Diving into the intricacies of this domain, this exclusive interview explores the distinctions between two key approaches – autologous and allogeneic cell therapies. We look at the nuances of cell sourcing, preclinical…
In the pursuit of a remedy for Alzheimer's disease, a frontier in medical science is illuminating a glimmer of hope. Stem cell therapies have already demonstrated their prowess in treating diverse cancers and ailments linked to the blood and immune system.
We are thrilled to announce the winner of the Drug Target Review x ELRIG's Article Competition: Dr Rosa Woldegebriel, Lead Scientist at the Human Centric Drug Discovery in Oxford, UK, whose article titled "Advancing Drug Discovery for Pain Disorders: Human iPSC-Based Approach" presents a revolutionary method in pharmaceutical research. Addressing…
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Theonie Anastassiadis, Cofounder & Chief Innovation Officer of Alltrna and Senior Principal of Flagship Pioneering. As a senior principal at Flagship Pioneering, Theonie conceives,…
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
In this interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, we discover research uncovering a central factor contributing to anti-PD-1 resistance in cancer immunotherapy.
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.
We exclusively interview Dr Ali Roghanian, Associate Professor at the University of Southampton, UK, Ali is a leading researcher at the forefront of immunotherapy advancements. With a keen focus on the inhibitory IgG FcγRIIB receptor, join us as we dive into Ali’s findings, showcasing the complexities of FcγRIIB and its…
Scientists have developed a promising new method to detect cancer at very early stages during routine health screens, paving way for improved treatment and recovery.
Researchers from UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine have made a discovery linking the notorious cancer-causing gene, Myc, to the process of ageing.
A new discovery presents a bioinformatic approach for improving vaccine effectiveness against infectious agents such as COVID-19.
A new discovery from the University of Southern California (USC) on cancer metastasis has opened up new possibilities for combating the spread of this devastating disease.
